HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demirer, T. Articles by Bensinger, W. I. Search for Related Content PubMed PubMed Citation Articles by Demirer, T. Articles by Bensinger, W. I.

Optimization of Peripheral Blood Stem Cell Mobilization

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Key Words. Peripheral blood stem cell • Stem cell collections • Hematopoietic growth factors • Chemotherapy

Dr. Taner Demirer, The Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104, USA.

Peripheral blood stem cells (PBSC) are increasingly utilized in lieu of marrow for hematopoietic support due to the ease of collection and the rapid kinetics of recovery relative to bone marrow (BM). Neutrophil and platelet recovery times after PBSC transplantation average less than 8-12 days after infusion in contrast to the usual two to four weeks experienced after BM transplantation. This has simplified autologous transplantation and made it safer because patients require fewer days of antibiotic and blood component support and are discharged earlier from the hospital. The administration of hematopoietic growth factors during recovery from high-dose chemotherapy increases the number of circulating hematopoietic progenitor cells to levels as much as 1,000-fold greater than levels normally found in blood and 10-50 times greater than with chemotherapy alone. More recently, it has been shown that adequate numbers of PBSC can be collected using growth factors alone without prior chemotherapy. Although not yet universally accepted, the CD34⁺ cell content of PBSC appears to be the single most powerful predictor of recovery kinetics in patients receiving myeloablative therapy and PBSC infusion. Infusion of >5 x 10⁶ CD34⁺ cells/kg is associated with a rapid engraftment of neutrophils and platelets, although successful engraftment has also been reported with the infusion of 2.5-5 x 10⁶ CD34⁺ cells/kg. By measuring the CD34 or colony forming units-granulocyte-macrophage (CFU-GM) content of PBSC collections, mobilization chemotherapy and cytokine regimens, age, marrow disease, prior radiation and prior chemotherapy treatment have been found to be important factors influencing the numbers of stem cells collected. The current challenge for clinical investigators is to improve methods of identifying patients who will fail to mobilize sufficient numbers of PBSC prior to collection and to utilize new strategies for stem cell mobilization. The relative ease of collection and the rapid engraftment after myeloablative therapy suggest that PBSC will likely supplant marrow for both allogeneic and autologous transplantation in the next five years.

This article has been cited by other articles:

				Y. Gazitt, P. Shaughnessy, and Q. Liu Expression of Adhesion Molecules on CD34+ Cells in Peripheral Blood of Non-Hodgkin's Lymphoma Patients Mobilized with Different Growth Factors Stem Cells, February 1, 2001; 19(2): 134 - 143. [Abstract] [Full Text]

				Y. Gazitt and Q. Liu Plasma Levels of SDF-1 and Expression of SDF-1 Receptor on CD34+ Cells in Mobilized Peripheral Blood of Non-Hodgkin's Lymphoma Patients Stem Cells, January 1, 2001; 19(1): 37 - 45. [Abstract] [Full Text]

				Y. Gazitt Immunologic Profiles of Effector Cells and Peripheral Blood Stem Cells Mobilized with Different Hematopoietic Growth Factors Stem Cells, November 1, 2000; 18(6): 390 - 398. [Abstract] [Full Text]

				J. F. DiPersio, M. W. Schuster, C. N. Abboud, J. N. Winter, V. R. Santos, D. M. Collins, J. W. Sherman, and C. M. Baum Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma J. Clin. Oncol., July 14, 2000; 18(14): 2762 - 2771. [Abstract] [Full Text] [PDF]

				E. J. Shpall, C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, K. F. Mangan, S. F. Williams, C. F. LeMaistre, et al. A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients Blood, April 15, 1999; 93(8): 2491 - 2501. [Abstract] [Full Text] [PDF]

				C.H. Weaver, W. West, L. Schwartzberg, R. Birch, and C.D. Buckner The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers Oncologist, October 1, 1998; 3(5): 346 - 353. [Abstract] [Full Text]

				M.L. Patchen, J. Liang, T. Vaudrain, T. Martin, D. Melican, S. Zhong, M. Stewart, and P.J. Quesenberry Mobilization of Peripheral Blood Progenitor Cells by Betafectin(R) PGG-Glucan Alone and in Combination with Granulocyte Colony-Stimulating Factor Stem Cells, May 1, 1998; 16(3): 208 - 217. [Abstract] [Full Text]

				N. Ketterer, G. Salles, M. Raba, D. Espinouse, A. Sonet, P. Tremisi, C. Dumontet, I. Moullet, A. Eljaafari-Corbin, E.-M. Neidhardt-Berard, et al. High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation Blood, May 1, 1998; 91(9): 3148 - 3155. [Abstract] [Full Text] [PDF]

				J.A. Glaspy, E.J. Shpall, C.F. LeMaistre, R.A. Briddell, D.M. Menchaca, S.A. Turner, M. Lill, L. Chap, R. Jones, M.D. Wiers, et al. Peripheral Blood Progenitor Cell Mobilization Using Stem Cell Factor in Combination With Filgrastim in Breast Cancer Patients Blood, October 15, 1997; 90(8): 2939 - 2951. [Abstract] [Full Text] [PDF]